Evidence map›Paper›PMID 36578263›Full record

ArticleCurrent Alzheimer research2022

The Gut Microbiome and Alzheimer's Disease: A Growing Relationship.

Maroun Bou Zerdan, Elsa Hebbo, Ali Hijazi, Maria El Gemayel, Janane Nasr, Dayana Nasr, Marita Yaghi, Youssef Bouferraa, Arun Nagarajan

Abstract read
PubMed Publisher
In one paragraph

Article in Current Alzheimer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Gut-brain axis in health and brain disease.Chinese medical journal · 2026
    Review
  3. Review
  4. Open medicine (Warsaw, Poland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Interactions and Insertion ofInternational journal of molecular sciences · 2023
    Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Maroun Bou ZerdanDepartment of Internal Medicine, SUNY Upstate Medical University, New York, USA.
Elsa HebboFaculty of Medicine, American University of Beirut, Beirut 2020, Lebanon.
Ali HijaziFaculty of Medicine, American University of Beirut, Beirut 2020, Lebanon.
Maria El GemayelDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Hotel-Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.
Janane NasrFaculty of Medicine, Saint George Hospital, University of Balamand, Beirut, 1100, Lebanon.
Dayana NasrDepartment of Internal Medicine, SUNY Upstate Medical University, New York, USA.
Marita YaghiDepartment of Hematology and Oncology, Cleveland Clinic Florida, Weston, Florida, USA.
Youssef BouferraaDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, USA.
Arun NagarajanDepartment of Hematology/Oncology, Cleveland Clinic, Weston, FL, 33331, USA.
American University of Beirut · LBCleveland Clinic · USCleveland Clinic Florida · USSaint George Hospital · LBSaint Joseph University · LBSUNY Upstate Medical University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence that the gut microbiota plays a key role in the pathogenesis of Alzheimer's disease is already unravelling. The microbiota-gut-brain axis is a bidirectional communication system that is not fully understood but includes neural, immune, endocrine, and metabolic pathways. The progression of Alzheimer's disease is supported by mechanisms related to the imbalance in the gut microbiota and the development of amyloid plaques in the brain, which are at the origin of Alzheimer's disease. Alterations in the composition of the gut microbiome led to dysregulation in the pathways governing this system. This leads to neurodegeneration through neuroinflammation and neurotransmitter dysregulation. Neurodegeneration and disruption of the blood-brain barrier are frontiers at the origin of Alzheimer's disease. Furthermore, bacteria populating the gut microbiota can secrete large amounts of amyloid proteins and lipopolysaccharides, which modulate signaling pathways and alter the production of proinflammatory cytokines associated with the pathogenesis of Alzheimer's disease. Importantly, through molecular mimicry, bacterial amyloids may elicit cross-seeding of misfolding and induce microglial priming at different levels of the brain-gut-microbiota axis. The potential mechanisms of amyloid spreading include neuron-to-neuron or distal neuron spreading, direct blood-brain barrier crossing, or via other cells such as astrocytes, fibroblasts, microglia, and immune system cells. Gut microbiota metabolites, including short-chain fatty acids, pro-inflammatory factors, and neurotransmitters may also affect AD pathogenesis and associated cognitive decline. The purpose of this review is to summarize and discuss the current findings that may elucidate the role of gut microbiota in the development of Alzheimer's disease. Understanding the underlying mechanisms may provide new insights into novel therapeutic strategies for Alzheimer's disease, such as probiotics and targeted oligosaccharides.

Indexed as

Alzheimer’s diseaseblood-brain barrier.dysbiosisgut microbiomeneurodegenerationneuroinflammation

Identifiers

PMID36578263
OpenAlexW4313279030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.